Scientist: Aroon Hingorani

Aaroon Hingorani ESMH scientistAroon Hingorani is UCL Professor of Genetic Epidemiology; Director of the UCL Institute of Cardiovascular Science; Cardiovascular Programme Lead for the UCL Hospitals NIHR Biomedical Research Centre; Director of the UCL British Heart Foundation Research Accelerator; and co-Investigator in the Understanding Mechanisms of Disease Initiative in Health Data Research UK. He is Consultant Physician at University College London Hospitals NHS Foundation Trust and an NIHR Senior Investigator.

His current work focuses on the use of genetic studies in populations as a tool to identify and validate drug targets, using the Mendelian randomisation principle, to improve efficiency in pharmaceutical development. He also has an interest in critical evaluation of the use of genomic and biomarker data for disease prediction and stratification.

A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research

A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research

Re-engineering pharmaceutical research, a scientist’s opinion Interview with Aroon Hingorani, Professor of Genetic Epidemiology at University College London. Could you speculate what you think are the biggest causes of drug failure? It is well recognised that the number one cause for drug failure is a lack of efficacy of the drug in the intended indication, ...

Re-engineering pharmaceutical research for better patient outcomes

Re-engineering pharmaceutical research for better patient outcomes

A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?